Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06033248 · ClinicalTrials.gov registry record

Using Urine Samples to Identify Lung Cancer

A clinical trial of Non-Small Cell Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
210
Enrollment target
7
Study locations

NCT06033248: Recruiting study of Non-Small Cell Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT06033248 is a study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 210 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (68% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06033248, a study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
210 participants
Enrollment target
7
Study locations

Study Summary

The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC. The ABP test uses laboratory animals that are trained to detect (by smell) different chemicals in urine. Studies show that people with lung cancer have unique chemicals in their urine that are not present in people without lung cancer, and researchers think these chemicals can be used to identify people with lung cancer without the need for invasive procedures (like biopsy).

Primary Outcome

in urine samples

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST urine sample

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2023-08-24
Est. Completion 2026-08
Memorial Sloan Kettering Cancer Center

1,884 total trials

What NCT06033248 shows while recruiting

NCT06033248 is an observational study that tracks outcomes without assigning an intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (68% lower).

The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which urine sample is the first listed.

NCT06033248 lists 7 locations in 2 states (New York, New Jersey).

Frequently Asked Questions

What is clinical trial NCT06033248 about?

NCT06033248 is a clinical study titled "Using Urine Samples to Identify Lung Cancer". The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC. The ABP test uses laboratory animals that a...

What is the current status of trial NCT06033248?

This trial is currently recruiting. The enrollment target is 210 participants. The study started on 2023-08-24. Estimated completion is 2026-08.

What conditions does trial NCT06033248 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT06033248?

The interventions under investigation include: urine sample (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06033248?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06033248 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06033248's enrollment target sits among peer trials

210 160th of 454 higher than 294 of 454 other Non-Small Cell Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02665923 · 210 participants

    Gastric Emptying in Neonates and Infants After Formula Feeding

  • NCT03322891 · 210 participants · NA

    Improving Health Literacy in African-American Prostate Cancer Patients

  • NCT03544489 · 210 participants · Phase 2

    Effectiveness of Exercise After an ICD

  • NCT04408430 · 210 participants · NA

    The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06033248, the US trial registry maintained by the National Library of Medicine. NCT06033248 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.